Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new ...

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked ...

Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its ...

Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics. | ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...